Erasca, Inc.
NASDAQ:ERASBiotechnology
-$0.02 today
- Market cap
- $4.83B
- Beta
- 0.73
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.91
Volume 8.94M
Average 6.79M
ERAS Total Liabilities
Everything the company owes to creditors and other parties.
Erasca, Inc.NASDAQ: ERAS
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities rises 13.4% from a year ago
Total liabilities stood at $82.2M at the end of Q3 FY2026, up 13.4% from a year earlier and up 12.3% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.
Context
- Total liabilities amounted to 8.2% of total assets at the end of Q3 FY2026, down 9.0 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +13.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 70.98M USD
- Year-over-year change
- -10.2%
- 4-year CAGR
- +12.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.98M | -10.2% |
| FY2024 | 2024-12-31 | 79.03M | +0.5% |
| FY2023 | 2023-12-31 | 78.61M | -23.7% |
| FY2022 | 2022-12-31 | 103.06M | +129.6% |
| FY2021 | 2021-12-31 | 44.89M | — |
Total Liabilities vs competitors
How ERAS compares with its peers on the latest reported figures
- ERAS's Sep 2026 total liabilities of $82.2M is the 6th highest of the 9 companies compared; the peer median is $119.56M.
- Its year-over-year change of +13.4% is the 6th highest of 9, against a peer median of +32.6%.
- Total liabilities amounts to 8.2% of total assets for ERAS, versus a peer median of 24.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.72B | +204.3% | +78.7% | 39.7% | |
| Mar 2026 | $544.67M | +43.6% | +150.2% | 83.5% | |
| Jun 2026 | $490.64M | +78.9% | +156.8% | 65.9% | |
| Mar 2026 | $146.03M | -11.0% | +58.4% | 64.1% | |
| Mar 2026 | $93.08M | +21.7% | +30.9% | 9.0% | |
| Sep 2026 | $82.2M | +13.4% | -11.7% | 8.2% | |
| Sep 2026 | $53.29M | +6.4% | -34.5% | 5.2% | |
| Mar 2026 | $25.32M | +95.4% | +45.8% | 7.2% | |
| Mar 2026 | $21.21M | -8.3% | -1.7% | 4.9% | |
| Peer median (excluding ERAS) | $119.56M | +32.6% | +52.1% | 24.4% | |
Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 360.49M | 284.22M | 93.08M | 67.74M | 73.81M |
| Short-term Investments | 53.99M | 151.4M | 219.28M | 230.57M | 202.27M |
| Net Receivables | 0 | 0 | 0 | 2.3M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 100K | 748K | 1.1M | 8.18M | 7.66M |
| Total Current Assets | 420.02M | 444.5M | 320.68M | 308.79M | 286.24M |
| Property, Plant & Equipment (Net) | 33.31M | 65.23M | 60.19M | 48.54M | 42.33M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 44.77M | 2M | 10.05M | 142.16M | 66.13M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.32M | 3.18M | 4.38M | 3.03M | 1.45M |
| Total Non-current Assets | 81.4M | 70.41M | 74.62M | 193.73M | 109.92M |
| Total Assets | 501.42M | 514.91M | 395.3M | 502.53M | 396.15M |
| Account Payables | 4.68M | 23.05M | 2M | 468K | 981K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.16M | 2.33M | 10.78M | 10.65M | 12.07M |
| Total Current Liabilities | 26.22M | 48.69M | 26.16M | 31.4M | 28.51M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 158K | 573K | 566K | 362K | 399K |
| Total Non-current Liabilities | 18.66M | 54.37M | 52.46M | 47.63M | 42.47M |
| Total Liabilities | 44.89M | 103.06M | 78.61M | 79.03M | 70.98M |
| Common Stock | 12K | 15K | 15K | 28K | 28K |
| Retained Earnings | (238.17M) | (480.97M) | (606.01M) | (767.66M) | (892.21M) |
| Accumulated OCI | (162K) | (1.04M) | 77K | 405K | 628K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 456.53M | 411.85M | 316.69M | 423.5M | 325.17M |
| Total Debt | 18.79M | 55.1M | 55.86M | 51.89M | 47.14M |
| Net Debt | (341.7M) | (229.12M) | (37.22M) | (15.85M) | (26.67M) |
Erasca, Inc.
NASDAQ:ERAS
Intrinsic Alpha fair value
Locked
Current Price
$13.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.